Diagnosis, clinicopathological characteristics and prognosis of pulmonary mucinous adenocarcinoma

Primary pulmonary mucinous adenocarcinoma (PPMA) is an uncommon subtype of lung adenocarcinoma. The present study attempted to clarify the diagnosis, clinicopathological characteristics, and pathologic significance of epithelial growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (K...

Full description

Saved in:
Bibliographic Details
Published inOncology letters Vol. 15; no. 1; pp. 489 - 494
Main Authors Sun, Fei, Wang, Pengcheng, Zheng, Yiming, Jia, Weiguang, Liu, Fuxing, Xiao, Wei, Bao, Jingjing, Wang, Song, Lu, Kaijin
Format Journal Article
LanguageEnglish
Published Greece Spandidos Publications 01.01.2018
Spandidos Publications UK Ltd
D.A. Spandidos
Subjects
Adenocarcinoma
Cancer therapies
Care and treatment
Classification
Diagnosis
Growth factors
Lung cancer
Medical diagnosis
Medical prognosis
Medical research
Mutation
Patients
Sarcoma
Studies
Tumors
Beijing China
United States > US
China
mucinous adenocarcinoma
Kirsten rat sarcoma viral oncogene
epithelial growth factor receptor
Online AccessGet full text

Cover

More Information
Summary:Primary pulmonary mucinous adenocarcinoma (PPMA) is an uncommon subtype of lung adenocarcinoma. The present study attempted to clarify the diagnosis, clinicopathological characteristics, and pathologic significance of epithelial growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene (KRAS) mutations and the prognosis of PPMA. A total of 29 patients with PPMA from among 1,469 surgically resected patients with lung adenocarcinoma were enrolled. All of the tumours expressed CK7 and 5 cases exhibited co-expression with CK20. A total of 8 cases expressed EGFR, 14 cases expressed P53 and 2 cases expressed CEA. The majority of mucinous adenocarcinomas expressed thyroid transcription factor 1, Napsin A, Villin and Cam5.2 proteins. KRAS mutations were observed in 62% of patients and were more prevalent in the lower lung lobe and in patients with invasive mucinous adenocarcinoma. A total of 2 cases exhibited an EGFR mutation, and the co-mutation of KRAS and EGFR was only detected in 1 case. The relapse-free and overall survival rates at 5 years were 70.4, and 81.5%, respectively. The results may assist to identify a molecular target and supply important information for a therapeutic strategy for patients with PPMA.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2017.7312